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ABSTRACT

Objective: To study the association between hormonal exposures and disease onset in a cohort of
women with neuromyelitis optica spectrum disorder (NMOSD).
Methods: Reproductive history and hormone use were assessed using a standardized reproductive survey administered to women with NMOSD (82% aquaporin-4 antibody positive) at 8 clinical
centers. Using multivariable regression, we examined the association between reproductive
exposures and age at first symptom onset (FS).

Results: Among 217 respondents, the mean age at menarche was 12.8 years (SD 1.7). The mean
number of pregnancies was 2.1 (SD 1.6), including 0.3 (SD 0.7) occurring after onset of NMOSD
symptoms. In the 117 participants who were postmenopausal at the time of the questionnaire,
70% reported natural menopause (mean age: 48.9 years [SD 3.9]); fewer than 30% reported
systemic hormone therapy (HT) use. Mean FS age was 40.1 years (SD 14.2). Ever-use of systemic hormonal contraceptives (HC) was marginally associated with earlier FS (39 vs 43 years,
p 5 0.05). Because HC use may decrease parity, when we included both variables in the model,
the association between HC use and FS age became more significant (estimate 5 2.7, p 5
0.007). Among postmenopausal participants, 24% reported NMOSD onset within 2 years of
(before or after) menopause. Among these participants, there was no association between age
at menopause or HT use and age at NMOSD onset.
Conclusions: Overall, age at NMOSD onset did not show a strong relationship with endogenous
hormonal exposures. An earlier onset age did appear to be marginally associated with systemic
HC exposure, an association that requires confirmation in future studies. Neurol Neuroimmunol
Neuroinflamm 2017;4:e339; doi: 10.1212/NXI.0000000000000339
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FS 5 first symptom onset; HC 5 hormonal contraceptives; HT 5 hormone therapy; NMO 5 neuromyelitis optica; NMOSD 5
neuromyelitis optica spectrum disorder.

Neuromyelitis optica (NMO) is a severe inflammatory neurologic disease, whose main clinical
manifestations are simultaneous or successive episodes of optic neuritis and transverse myelitis.
NMO is associated with serum immunoglobulin G antibodies to aquaporin-4, which are present in about 75% of patients with NMO. “NMO-spectrum disorders” (NMOSDs) is a unifying
term to describe the clinical spectrum of NMO, including aquaporin-4 antibody–positive patients with limited forms of the disease. The female-to-male ratio in NMOSD is up to 9:1,1,2 but
the role of sex-specific hormones in disease pathogenesis has not been explored.
In MS, another CNS demyelinating disease with high female:male ratio (2–3:1 and possibly
increasing3,4), earlier age at menarche is associated with earlier age at MS onset. Pregnancy
reduces the risk of an MS relapse,5,6 and increasing parity is associated with lower risk of
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long-term disease progression.7 In NMOSD,
the risk of relapses and of first disease onset is
increased during the pregnancy and postpartum periods relative to baseline.8–11
In this cohort study, we hypothesized that,
as seen in MS, both exogenous and endogenous
hormonal exposures are associated with age at
NMOSD onset. First, we describe the reproductive exposures of an international multicenter cohort of women with NMOSD; second,
we examine the association between these hormonal exposures and age at disease onset.
METHODS Setting. A standardized reproductive survey was
conducted between June 2011 and May 2013 for women with
NMOSD (82% antibody positive) at 8 clinical centers, who were
identified by chart review. These centers were as follows: Walton
Centre in Liverpool, England (n 5 56), Mayo Clinic-Rochester
(n 5 39), Washington University in St. Louis (n 5 36), Charité Universitätsmedizin Berlin (n 5 26), Mayo Clinic-Scottsdale (n 5
25), Johns Hopkins University (n 5 19), and Massachusetts
General Hospital/Brigham and Women’s Hospital (n 5 16).

Standard protocol approvals, registrations, and patient
consents. Informed consent was obtained from all participants
under institutional review board policies at each site.

Participants. A total of 217 women who met current published
diagnostic criteria for NMOSD with or without aquaporin-4
antibodies12 were enrolled consecutively, and all participants
completed at least 1 component of the questionnaire.
Questionnaire. The reproductive survey included questions
about menarche, pregnancies, menopause, and exogenous hormones.13 It was conducted using REDCap, a secure Health Insurance Portability and Accountability Act compliant web-based
survey tool. This questionnaire had previously good concordance
of selected variables against the medical record in women with
MS.14 For this study, the following variables were examined:
1. Age at menarche.
2. Hormonal contraceptive (HC) use: Ever-use of HC was further divided by administration (oral, transdermal, IM) and
duration (less than, vs at least, 12 months). The 12-month
duration was selected because analyzing HC use over shorter
timeframes might introduce more substantial recall bias. The
formulation (estrogen, progestogen, or combined) or dosing of
HC was not assessed.
3. Number of pregnancies, including lifetime and after NMOSD
first symptom onset (FS).
4. Current reproductive status was categorized as cycling, perimenopausal (last menses in the 3–12 months prior to survey),
or postmenopausal (no menses in the prior 12 months or loss
of menses due to surgery). Type was categorized as (1) natural,
or resulting from (2) surgical intervention (hysterectomy and/
or bilateral oophorectomy) or (3) chemotherapy or radiation.
Menopausal Age was defined as last menstrual period beyond
which no menses occurred for 1 year (natural) or surgery date,
according to Stages of Reproductive Aging Workshop 110
guidelines.15
5. Menopausal hormone therapy (HT) use was categorized
dichotomously for type (estrogen and/or progestogens vs other
types [black cohosh, testosterone, etc]) and administration
2
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(systemic [patch 1 oral] vs local [gel, cream, and ring]), and
for this analysis we included only systemic, homone-based HT.

Statistical analysis. Descriptive statistics were used to summarize demographic, clinical, and reproductive characteristics. To
examine the association between reproductive exposures and reported age at FS, we used multivariable regressions. Data were
analyzed using the SAS-based software program JMP, version
8.0.1 (SAS Institute, Cary, NC).
RESULTS Study population. The demographic and
disease characteristics of the 217 respondents are provided in table 1. Mean FS age was 40.1 years (SD 14.2,
median 39.8, and interquartile range 28.0–51.6).
There was no relationship between FS age and
NMO antibody positivity (x2, p 5 0.68). With respect
to hormonal exposures, the mean age at menarche was
12.8 years (SD 1.7), and 61% of women reported
systemic oral HC use for at least 12-month duration.
The median number of total pregnancies was 2 (SD
1.6) and occurring after NMOSD FS was 0 (SD 0.7).
Thirteen percentage of respondents (26/193) reported
delay in achieving pregnancy of 12 months or longer,
and in the 11 in whom a reason for their infertility was
identified, the causes were as follows: ovarian cysts
(n 5 3), structural problems (n 5 3, including 1
endometriosis), hormonal dysregulation (n 5 3), and
male factors (n 5 2). Twelve participants (6%) reported receiving infertility treatment.
Among the 117 postmenopausal participants, 70%
(n 5 82) reported natural menopause (mean age: 48.9
years [SD 3.9]); only 25% (n 5 29) reported systemic
HT use. Given prior reports that women with neurologic disabilities may access fewer components of general health promotion (such as cancer screening,16 or
HT, which was often “standard of care” during the
epoch corresponding to this cohort’s menopausal transition17), we compared HT use in postmenopausal
participants with FS occurring before vs after their final
menstrual period. Women with FS after their menopause reported greater HT use (37%) than women
with FS prior to menopause (16%; x2 test 5 5.68,
p 5 0.016). Association between reproductive exposures and age at disease onset is summarized in table 2:

Menarche. Ten participants (4.6%) reported FS prior
to age of 18, 7 of whom reported FS within 2 years
prior to (n 5 2) or after (n 5 5) menarche. There
was no association between FS age and menarcheal age
(linear regression, estimate 5 0.91, p 5 0.12).
HC use. Ever-use of systemic HC was associated

with earlier FS (39.3 vs 43.4 years), but this was
marginally significant (linear regression, estimate 5
2.1, p 5 0.05; figure).
Parity. A later FS was also associated with a greater

number of preceding pregnancies (estimate 5 3.3,
p , 0.0001). Because participant age confounded

Table 1

Demographic, clinical, and reproductive characteristics of 217 women with NMOSD from 8
participating clinical centers
Mean (SD) or n (%)

Range

n

49.4 (14.3)

17–83

217

Demographic characteristics
Age survey, y
Race

217

Caucasian

165 (76)

Black or African American

36 (17)

Asian

12 (6)

Other

4 (2)

Ethnicity
Hispanic

198
9 (5)

Marital status

217

Married

133 (61)

Single

50 (23)

Divorced

22 (10)

Widowed

12 (6)

Disease characteristics
Age at first symptoms

40.1 (14.2)

10–76

NMO antibody test

217
214

Positive

175 (82)

Negative

36 (17)

Does not know

3 (1)

Reproductive characteristics
Age at menarche

12.8 (1.7)

9–23; IQR 12–14

Ever pregnant

214
217

Yes

172 (79)

No

45 (21)

No. of pregnancies
Total

2.1 (1.6); median: 2

0–6

212

Prior to NMOSD first symptoms

1.9 (1.6); median: 2

0–6

210

After NMOSD first symptoms

0.3 (0.7); median: 0

0–4

210

Ever-use of systemic HC

212

Yes

148 (70)

No

64 (30)

Systemic HC use
None

64 (30)

Oral, <12 mo

13 (6)

Oral, ‡12 mo

127 (61)

Transdermal, IM

3 (1)

Current reproductive status

207

217

Cycling

91 (42)

Perimenopausal

9 (4)

Postmenopausal

117 (54)

Postmenopausal only
Menopausal type
Natural

117
82 (70)

Continued
Neurology: Neuroimmunology & Neuroinflammation
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Table 1

Continued
Mean (SD) or n (%)

Bilateral oophorectomy

18 (15)

Hysterectomy and/or unilateral oophorectomy

7 (6)

Chemotherapy

9 (8)

Radiation

1 (1)

Range

Systemic HT use

n

116

None

81 (70)

Estrogen

25 (22)

Estrogen 1 progestin

4 (3)

Other or missing

6 (5)

Abbreviations: HC 5 hormonal contraceptive; HT 5 hormone therapy; IQR 5 interquartile range; NMO 5 neuromyelitis
optica; NMOSD 5 neuromyelitis optica spectrum disorder.

the interpretation (i.e., parity increases with age),
we categorized individuals according to FS age
(before 30, 30–39, 40–49, and 50 years and older).
When we included this categorical term in the linear regression model, the association between FS
age and number of preceding pregnancies was not
significant (linear regression, estimate 5 0.30,
p 5 0.16).
Because HC use might result in lower parity, we
included both parity and HC use in a linear regression
model, and the association between HC use and FS
age became more significant (linear regression, estimate 5 2.7, p 5 0.007); the number of preonset
pregnancies remained significant (linear regression,
estimate 5 3.3, p , 0.0001).

Table 2

Menopause. Among the 106 women who were post-

menopausal at the time of the survey and who provided
a menopausal age, there was no relationship between
age at menopause and FS age (linear regression, estimate 5 0.30, p 5 0.10). Among these women, 59
(56%) reported FS after their final menstrual period
and 25 (24%) reported FS within 2 years of their final
menstrual period (n 5 18 before and n 5 7 after). In
women with postmenopausal onset of FS, there was no
relationship between systemic HT use and FS age (linear regression, estimate 5 0.95, p 5 0.66).
In sensitivity analyses, the significance of the findings reported was unchanged when we included race,
ethnicity, and NMO antibody positivity as covariates
in the models.

Summary of results
Model

N

All respondents
Menarcheal age

Linear regression

Estimate 5 0.91, p 5 0.12

Parity

Linear regression

Estimate 5 3.3, p , 0.0001a

Linear regression, adjusting for FS
age categoryb

Estimate 5 0.30, p 5 0.16

Systemic HC usec

Linear regression

Estimate 5 2.1, p 5 0.05a (never-users had later
FS than ever-users: 43.4 vs 39.3 y)

Parity and HC use

Linear regression, including both
parity and HC use

Estimate for parity 5 3.3, p , 0.0001a;
estimate for HC use 5 2.7, p 5 0.007a

Linear regression

Estimate 5 0.30, p 5 0.10

Linear regression

Estimate 5 0.95, p 5 0.66

Postmenopausal respondents only
(N 5 106)
Age at menopause
Participants with postmenopausal
onset only (N 5 59)
Systemic HT use

Abbreviations: FS 5 first symptom onset; HC 5 hormonal contraceptive; HT 5 hormone therapy.
a
Significant.
b
Before 30, 30–39, 40–49, and 50 years and older.
c
Categorized as never-use vs 12 months or more.
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Figure

Age at NMOSD first symptom onset in women with and without prior
exposure to systemic hormonal contraceptives

NMOSD 5 neuromyelitis optica spectrum disorder.

DISCUSSION This study, conducted in a large international survey of women with NMOSD, represents
a preliminary analysis of the relationship from
NMOSD onset to hormonal factors beyond pregnancy.
With respect to endogenous exposures, unlike in
MS, we saw no association between menarcheal age
and NMOSD onset.18–21 As in other cohorts, 5% of
our participants reported FS before the age of 18.2,22
The association between a greater number of preceding
pregnancies and later NMOSD FS (p , 0.0001) was
expected, as parity increases with age. Future studies
should examine the association between age at first offspring’s birth (not available in our cohort) and FS age.
It is important that the number of pregnancies after
disease onset was far outnumbered by those prior to
disease onset. While this may partly reflect the older age
of women at FS, it may also reflect reproductive choices
relating to uncertainty of disease course, need for new
medications that have uncertain effects on a fetus, and
concerns about the future ability to care for a child, as
has been reported in MS.23 Inclusion of NMO antibody positivity in the sensitivity analyses did not
change the significance (or nonsignificance) of the relationship between endogenous hormonal exposures and
FS age. In a separate manuscript, we describe the association between pregnancy and relapses in this cohort
(Klawiter, personal communication). It is notable that
6% of the respondents reported use of fertility treatments. Larger case-control studies adjusting for participant age are needed to determine whether there is an
association between NMOSD and infertility.
With respect to exogenous exposures, we observed
a marginally significant association between ever-use

of HC and earlier age at NMOSD onset. From
a broader perspective, evidence for an association
between HC and autoimmune diseases is mixed
(including lower,24–26 neutral,27,28 and higher29 risk
of MS) and likely is confounded by changing HC
formulations across epochs. Furthermore, the confounding effect of delayed (or no) childbearing that
is achieved through HC use has not been adequately
assessed, nor has the effect of participant age on recall
of HC use. Follow-up studies are required to confirm
this association, and, if this is confirmed, to assess HC
dosing effects and whether the association is
causative.
Approximately, one-quarter of all participants reported a postmenopausal onset of FS, which contrasts
with MS, where fewer than 10% develop MS FS after
the age of 50.30 The detection rate of serum aquaporin4 autoantibodies has been reported to increase in
women relative to men particularly after the age of
50, suggesting an effect of reproductive immunosenescence on NMOSD features.22 We observed no relationship between FS age and reported NMO antibody
positivity.
The primary strengths of this multicenter study
include an international design with a relatively large
sample size, the use of specific diagnostic criteria for
NMOSD, and the use of a standardized fairly comprehensive reproductive survey. Still, numbers were overall low, participants were mostly Caucasians from
European and North American centers, possibly limiting generalizability of findings, occasionally data were
missing, and reliance on patient-reported hormonal exposures may have introduced recall bias. In addition,
we were not adequately powered to detect epochal factors potentially associated with both exogenous hormone use and NMOSD susceptibility or disease
course, or to detect differences across clinical centers.
We also identified further refinements needed to the
reproductive survey (e.g., age at first birth and HC
formulations).
While we selected age at NMOSD as our initial
clinical measure of interest, further studies should evaluate the association between endogenous and exogenous hormonal exposures and other NMOSD
characteristics of interest, including clinical severity
and progression, and severity of inflammation on MRI.
Studies that include detailed hormonal analysis
and immunopathogenetic measures are required to
replicate these results and further elucidate the role
of endogenous and exogenous hormonal exposures
on this female predominant autoimmune disease, as
well as important pathophysiologic implications.
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